T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics

Rhea-AI Filing Summary

T. Rowe Price Investment Management filed an amendment to a Schedule 13G/A reporting beneficial ownership of 3,137,558 shares of MapLight Therapeutics common stock, representing 7.4% of the class.

The filing lists sole voting power of 8,719,082 shares and sole dispositive power of 8,741,432 shares. The filing is signed by Ellen York, Vice President, dated 05/15/2026.

Key Figures

Beneficial ownership: 3,137,558 shares Percent of class: 7.4% Sole voting power: 8,719,082 shares +3 more

6 metrics

Beneficial ownership 3,137,558 shares Amount beneficially owned

Percent of class 7.4% Percent of class reported on Schedule 13G/A

Sole voting power 8,719,082 shares Sole power to vote or to direct the vote

Sole dispositive power 8,741,432 shares Sole power to dispose or to direct the disposition

CUSIP 56565P103 MapLight Therapeutics common stock

Signature date 05/15/2026 Filing signed by Ellen York, Vice President

Key Terms

Beneficially owned, Sole voting power, Sole dispositive power, Schedule 13G/A

4 terms

Beneficially owned regulatory

"Amount beneficially owned: 3137558"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole voting power regulatory

"Sole power to vote or to direct the vote: 8719082"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 8741432"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"Amendment to Schedule 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

MAPLIGHT THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

56565P103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 56565P103

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,719,082.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,741,432.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,137,558.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MAPLIGHT THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 56565P103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3137558
(b)	Percent of class: 7.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 8719082
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 8741432
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026

FAQ

What stake does T. Rowe Price hold in MapLight Therapeutics (MPLT)?

T. Rowe Price reports beneficial ownership of 3,137,558 shares, representing 7.4% of MapLight Therapeutics common stock. This figure is the amount listed under “Amount beneficially owned.”

What voting and dispositive powers does T. Rowe Price report for MPLT?

The filing shows sole voting power of 8,719,082 shares and sole dispositive power of 8,741,432 shares, as stated in the ownership table of the amendment.

What form was filed and when was it signed?

An amendment to a Schedule 13G/A was filed; the signature on the amendment is dated 05/15/2026, as shown on the filing excerpt.

Does T. Rowe Price claim beneficial ownership in the filing?

The filing includes a declaration denying that T. Rowe Price is the beneficial owner of the securities; the text states that such ownership is expressly denied by the filer.

What is the issuer and CUSIP on the filing?

The issuer is MapLight Therapeutics Inc and the CUSIP listed for the common stock is 56565P103, as shown on the cover information.